

WANBURY LIMITED

BSEI Tech Park, B-Wing, 10th Floor, Sector 30A, Opp. Vashi Railway Station, Vashi, Navi Mumbai - 400 705
Unaudited Financial Results for the Period ended 31st March 2008

(Rs in lacs)


Sr. No.	Particulars	For the Qtr Ended	For the Qtr Ended	For the Period Ended	For the Year Ended
		31-03-2008	31-3-2007	31-03-2008	31-03-2007
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
	INCOME				
1	Sales/ Income from operations	6,443.63	4,798.12	23,016.51	14,608.02
	Less : Excise Duty	115.77	58.72	494.35	225.27
	Net Sales/Income from Operation	6,327.86	4,739.40	22,522.16	14,382.75
2	Other Income	128.16	79.87	714.73	663.10
3	Total Income (1+2)	6,456.02	4,819.27	23,236.89	15,045.85
	EXPENDITURE				
4	a. (Increase)/Decrease in Stocks of WIP & Finished/Traded Goods	(588.90)	(163.80)	(703.90)	(276.73)
	b. Consumption of raw materials	2,868.15	1,198.94	8,705.95	4,126.62
	c. Purchase of traded goods	688.90	1,970.16	2,998.73	4,009.14
	d. Employees Cost	690.76	397.44	2,608.79	1,497.51
	e. Depreciation/Amortisation	241.76	61.37	570.32	270.77
	f. Other Expenditure	1,859.17	839.15	5,948.95	3,534.99
	g. Total	5,759.84	4,303.26	20,128.84	13,162.30
5	Interest (Net)	316.38	123.47	1,167.89	415.62
6	Exceptional items-Income/(Expense)	-	-	280.51	-
7	Profit (+)/Loss(-) from ordinary activity before tax (3)-(4+5)+(6)	379.80	392.54	2,220.67	1,467.93
8	Tax Expenses	(123.99)	68.97	(102.54)	586.90
	- Current Tax	42.23	162.04	248.23	373.65
	- MAT Credit Entitlement	(42.23)	(211.61)	(247.48)	-
	- MAT Credit Entitlement Utilised	-	-	-	7.00
	- Deferred Tax	(139.69)	-	(139.69)	56.27
	- Fringe Benefit Tax	15.69	5.54	36.39	30.24
	- Tax of Earlier Years	-	113.00	-	119.74
9	Net Profit from ordinary activity after Tax (7-8)	503.80	323.57	2,323.22	881.03
10	Extra ordinary items (Net of Tax Expenses)	-	-	-	-
11	Net Profit for the period (9-10)	503.80	323.57	2,323.22	881.03
12	Paid up Equity Share Capital	1,412.67	1,274.74	1,412.67	1,274.74
	Face value of the Equity Share (Rs)	10.00	10.00	10.00	10.00
13	Reserves excluding Revaluation reserve as per balance sheet of previous accounting year .				6,507.88
14	Earning Per Share (EPS)				
	a) Basic weighted EPS before extraordinary items (Not Annualised) Rs	3.65	2.54	16.83	6.91
	b) Basic weighted EPS after extraordinary items (Not Annualised) Rs	3.65	2.54	16.83	6.91
15	Public Shareholdings				
	- Number of Shares	8,581,206	7,055,135	8,581,206	7,055,135
	- Percentage of Shareholding	60.74	55.35	60.74	55.35

Notes :-

- 1) The above financial results have been reviewed by the Audit Committee and have been taken on record at the meeting of the Board of Directors of the Company held on 27th June, 2008 .
- 2) The Company has only one segment of activity namely "Pharmaceuticals".
- 3) During the quarter the Company has allotted :
 - (a) 1,24,004 Equity Shares of Rs. 10/- each at a premium of Rs. 128.43 per Equity Share, upon conversion of 30 bonds of Foreign Currency Convertible 'A' Bonds and
 - (b) 7,85,557 Equity Shares of Rs. 10/- each at par to the Equity Shareholders of Doctors Organic Chemicals Limited pursuant to the Order of Board for Industrial and Financial Reconstruction dated May 4, 2007.
- 4) The Company is in the process of ascertaining the final impact of Accounting Standard (Revised)15 "Employee Benefits" and will account for the same at the period end.
- 5) The market price of the equity shares of the Company being less than the exercise price in respect of various outstanding options to subscribe to equity shares, the aforesaid options are considered to be anti dilutive.
- 6) The Hon'ble Supreme Court vide its Order dated May 16, 2008 has set aside the Order of Hon'ble Board for Industrial and Financial Reconstruction (BIFR), approving the merger of The Pharmaceutical Products of India Limited (PPIL) with the Company and directed the BIFR to consider the matter afresh. Consequently, merger effect given in earlier year's accounts has been reversed, including effect on equity capital of Rs. 56.26 lacs.
- 7) Above includes results of Doctors Organic Chemicals Limited, which has been merged w.e.f, 1st April, 2007, being the appointed date, with the Company and to that extent figures for the current quarter / period are not comparable with those of the corresponding previous quarter/period.
- 8) The Company has changed its financial year. Consequently, current financial year shall comprise of 18 months ending on 30th September, 2008.
- 9) Exchange loss for the current quarter and period of Rs 539.31 lacs and Rs 503.74 lacs respectively is included in Other Expenditure and exchange gain for corresponding previous quarter and period of Rs 22.30 lacs and Rs 103.66 lacs respectively is included in Other Income.
- 10) There was no investor complaint pending at the beginning and at the end of the quarter. During the quarter, the Company had received and resolved 23 complaints.

Place : Mumbai

Date : 27th June 2008



K CHANDRAN

WHOLE-TIME DIRECTOR

WANBURY LIMITED
CONSOLIDATED UNAUDITED FINANCIAL HIGHLIGHTS
FOR THE QUARTER ENDED 31ST MARCH 2008

(Rs in lacs)

Particulars	For the Qtr Ended	For the Qtr Ended	For the Period Ended	For the Year Ended
	31-03-2008	31-3-2007	31-03-2008	31-03-2007
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
Turnover & other Income	11,440.76	8,709.42	38,535.60	22,336.02
EBIDTA	1,785.88	1,264.02	6,962.65	3,292.12
NET PROFIT AFTER TAX	380.77	350.32	2,929.44	1,272.31
EPS	2.70	2.75	20.74	9.98
The above financial highlights includes the financials of the subsidiary Cantabria Pharma S.L.(Spain).				